Transmedics Group Inc
TMDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.46B
Close$
$86.08
20.8% upside
Current Fair Value
20.8% upsideUndervalued by 20.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.46 Billion |
|---|---|
| Enterprise Value | $2.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $5.6 |
| Beta | 1.88 |
| Outstanding Shares | 34,384,207 |
Return
| Return on Equity | 34.80% |
|---|---|
| Return on Assets | 11.98% |
| Return on Invested Capital | 7.55% |
Valuation & Multiples
| P/E Ratio | 14.16 |
|---|---|
| PEG | -19.8 |
| Price to Sales | 3.96 |
| Price to Book Ratio | 5.09 |
| Enterprise Value to Revenue | 4.44 |
| Enterprise Value to EBIT | 27.84 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 1.66 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$0.62
Average shareholder expectationRevenue Estimate
$174.47 M
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$0.74
Average shareholder expectationRevenue Estimate
$189.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 85.04% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.63%▼ 104.86% |
|---|---|
| Total Invested | $37.14M▼ 98.97% |
| Investors Holding | 13▼ 420.00% |
ESG Score
No data
About Transmedics Group Inc
Relevant Senate Committees
Finance
Oversees Medicare and Medicaid; reimbursement rates set by this committee are the single most important factor for the commercial adoption of TMDX's technology.
Health, Education, Labor, and Pensions
This committee oversees the FDA, which is responsible for the approval and regulation of TMDX's medical devices.